ATG5 and Alzheimer disease: In closing, our data demonstrate that EZH2 affects VSMC loss and even pathologic process of AD via regulating ACD of VSMCs, which is mediated by suppressing ATG5 and ATG7 expression and MEK–ERK1/2 signaling.